Core Insights - Neuronetics, Inc. is a medical technology company focused on improving the quality of life for patients with neurohealth disorders through innovative treatments [4][5] - The company will present at the Canaccord Genuity 44th Annual Growth Conference on August 14, 2024, highlighting its commitment to investor engagement [4] Company Overview - Neuronetics is a global leader in neuroscience, emphasizing the importance of mental health alongside physical health [5] - The company's flagship product, NeuroStar Advanced Therapy, is a non-drug, noninvasive treatment designed for patients with major depressive disorder (MDD) and anxiety symptoms [5] - NeuroStar has delivered over 6.4 million treatments, establishing itself as the leading transcranial magnetic stimulation (TMS) treatment for MDD in adults [5] Product Details - NeuroStar is indicated for treating depressive episodes and reducing anxiety symptoms in adults who have not responded satisfactorily to previous antidepressant medications [5] - The treatment is also FDA-cleared as an adjunct for adults with obsessive-compulsive disorder and for adolescents aged 15-21 with MDD [5] - The company is dedicated to transforming lives through exceptional treatment outcomes [5]

MALVERN, Pa., July 30, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced that it entered into a debt facility of up to $90 million with Perceptive Advisors LLC (Perceptive). Under the term loan, Neuronetics received the first tranche of $50 million at closing. Part of the initial $50 million tranche will be used to ...

Group 1 - Neuronetics, Inc. plans to release its second quarter 2024 financial and operating results on August 12, 2024, prior to market open [1] - The company will host a conference call at 8:30 a.m. Eastern Time on the same day to review its results [1][4] Group 2 - Neuronetics is a leader in neuroscience, focusing on improving mental health through its NeuroStar Advanced Therapy, a non-drug, noninvasive treatment for neurohealth conditions [2] - NeuroStar is FDA-cleared for major depressive disorder (MDD) in adults and adolescents aged 15 and older, as well as for obsessive-compulsive disorder (OCD) and anxiety symptoms in adults with MDD [2] - The treatment has delivered over 6.4 million sessions and is supported by the largest clinical data set for TMS systems for depression, including the world's largest depression Outcomes Registry [2]

Core Insights - Aetna has updated its TMS coverage to include adolescents aged 15 and older with major depressive disorder (MDD), following FDA clearance for NeuroStar TMS as a first-line add-on treatment for this age group [4][5][9] - Neuronetics is the only TMS company with FDA clearance for adolescent treatment and has a dedicated health policy team to advocate for health policy updates [5][9] - Adolescent depression affects an estimated 4.3 million U.S. adolescents aged 15-21, impacting their academic performance, relationships, and emotional well-being [6] Company Overview - Neuronetics, Inc. is a medical technology company focused on improving the quality of life for patients with neurohealth disorders through its NeuroStar Advanced Therapy [4][7] - NeuroStar is a non-drug, noninvasive treatment indicated for MDD and is the leading TMS treatment for adults, with over 6.4 million treatments delivered [7] Industry Context - The policy update from Aetna reflects a growing trend among payers to expand adolescent coverage for TMS therapy, indicating a shift towards addressing mental health needs in younger populations [5][9] - The recognition of adolescent mental health treatment by major payors like Aetna is seen as a critical step in mitigating the mental health crisis among young people [9]

Medi-Cal is California's Medicaid healthcare program. It offers no-cost and low-cost health coverage for children and adults with limited income and resources who meet eligibility requirements. Medi-Cal policies impact 14.8 million covered lives in California. The TMS policy update will go into effect on August 1, 2024. Neuronetics is the first and only TMS company with FDA clearance for the treatment of adolescents and the only company in the industry with a dedicated health policy team that partners with ...

Medi-Cal is California's Medicaid healthcare program. It offers no-cost and low-cost health coverage for children and adults with limited income and resources who meet eligibility requirements. Medi-Cal policies impact 14.8 million covered lives in California. The TMS policy update will go into effect on August 1, 2024. "At a time when mental health services are more essential than ever, expanded access to NeuroStar TMS through Medi-Cal is a pivotal step in addressing the growing need for care among both ad ...

BCBS Michigan covers 4.9 million lives in the state of Michigan, and the policy includes TMS access for members 15-70 years of age. Cambia Health Solutions is the parent company of Regence BCBS, Asuris Health, and BridgeSpan Health, which covers 2.5 million lives throughout the states of Washington, Utah, Oregon, and Idaho. The policy allows TMS eligibility for ages consistent with device-specific FDA indication. The effective date for both policies is September 1, 2024. For more information about NeuroStar ...

BCBS Michigan covers 4.9 million lives in the state of Michigan, and the policy includes TMS access for members 15-70 years of age. Cambia Health Solutions is the parent company of Regence BCBS, Asuris Health, and BridgeSpan Health, which covers 2.5 million lives throughout the states of Washington, Utah, Oregon, and Idaho. The policy allows TMS eligibility for ages consistent with device-specific FDA indication. The effective date for both policies is September 1, 2024. BCBS of Michigan and Cambia's Regenc ...

Better Me Provider Program is an extensive commercial initiative to support practices committed to meeting patient care and responsiveness standards. These standards are developed in collaboration with TMS medical experts, ensuring prompt response times by a dedicated NeuroStar coordinator, who advises patients about the benefits of the entire course of NeuroStar treatment, along with optimizing websites and social media content to educate patients. It is designed to help people with major depressive disord ...

MALVERN, Pa., July 01, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced the national launch of the Better Me Provider (BMP) program, pioneering new standards in patient care and responsiveness to improve treatment accessibility within the mental health industry. The providers participating in the program are committed t ...